CompanyIntelligence | Neurocrine Biosciences, Inc.

The Consus Group provides critical intelligence for the
business, investor, and legal communities.

Documents can be downloaded immediately after purchase. Complete your order by clicking the Add-to-Cart button.

$42	Subscribers Preview	2000	Agreement	Arena Pharmaceuticals Inc.	Neurocrine Biosciences, Inc.
$59	Subscribers Preview	2003	Agreement for Purchase and Sale And Joint Escrow Instructions	Chicago Title; Neurocrine; Pfizer	Science Park; Paul Hastings
$89	Subscribers Preview	2003	Agreement for Purchase and Sale And Joint Escrow Instructions	Chicago Title; Neurocrine; Pfizer	Science Park; Paul Hastings
$91	Subscribers Preview	2003	Agreement for Purchase and Sale of Real Property and Escrow Instructions	Chicago Title; Neurocrine; Pardee	Pardee Homes; Brobeck Phleger
$41	Subscribers Preview	2004	Consent Agreement and Amendment	DOV Pharma; Neurocrine; Pfizer	Wyeth; Wyeth Holdings
$34	Subscribers Preview	2004	DOV Pharmaceutical, Inc. Announces Second Quarter 2004 Results	DOV Pharma; Merck	Neurocrine
$37	Subscribers Preview	2004	Neurocrine and Wyeth Satisfy Hart-Scott-Rodino Requirements for the Acquisition of Indiplon Royalty Stream	DOV Pharma; Neurocrine	Wyeth
$36	Subscribers Preview	2004	Neurocrine Biosciences Acquires Wyeths Indiplon Royalty Stream	DOV Pharma; Neurocrine	Wyeth
$35	Subscribers Preview	2002	Neurocrine Biosciences Amends Shareholder Rights Plan	Neurocrine Biosciences, Inc.	Robertson Stephens, Inc.
$38	Subscribers Preview	2001	Neurocrine Biosciences Announces Initiation of Phase I Clinical Trial with Orally Active GnRH Antagonist for Women's Health Disorders and Prostate Cancer	Henry Pan; Paul Hawran	Claudia Jones; Neurocrine
$40	Subscribers Preview	2003	Neurocrine Biosciences Announces the Appointment of Lloyd E. Flanders, Ph.D. to the Position of Senior Vice President of Development	Ligand Pharmaceuticals, Inc.	Neurocrine Biosciences, Inc.
$31	Subscribers Preview	2003	Neurocrine Biosciences Announces the Appointment of Robert J. Little to Senior Vice President of Commercial Operations	Neurocrine Biosciences, Inc.	Pharmacia Corp.
$33	Subscribers	2003	Neurocrine Biosciences Announces the Appointment of Wendell Wierenga to the Position of Executive Vice President Research and Development	Neurocrine Biosciences, Inc.
$32	Subscribers	2000	Neurocrine Biosciences Expands Diabetes Collaboration with Taisho Pharmaceuticals	Neurocrine Biosciences, Inc.	Taisho Pharmaceutical Co., Ltd.
$32	Subscribers Preview	2001	Neurocrine Biosciences Initiates Phase III Clinical Trial for NBI-34060 in Chronic (Primary) Insomnia	Henry Pan; Paul Hawran; Elizabeth Foster	Gary A. Lyons; Neurocrine
$35	Subscribers Preview	2003	Neurocrine Biosciences Reports First Quarter 2003 Results	GlaxoSmithKline; Neurocrine	Pharmacia
$32	Subscribers Preview	2004	Neurocrine Biosciences Reports First Quarter 2004 Results	GlaxoSmithKline; Neurocrine	Pfizer
$40	Subscribers	2004	Neurocrine Biosciences Reports Fourth Quarter and Year-End 2003 Results	GlaxoSmithKline plc	Neurocrine Biosciences, Inc.
$32	Subscribers	2003	Neurocrine Biosciences Reports Second Quarter 2003 Results	Neurocrine Biosciences, Inc.
$34	Subscribers	2003	Neurocrine Biosciences Reports Third Quarter 2003 Results	Neurocrine Biosciences, Inc.